We are live on
!
Find out more
BC
Broadwood Capital Portfolio holdings
AUM
$1.42B
1-Year Est. Return
34.72%
This Fund
S&P 500
This Quarter
Est. Return
+21.75%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$867M
AUM Growth
+$147M
(+20%)
Cap. Flow
+$2.12M
Cap. Flow
% of AUM
0.24%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$2.12M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.27% |
| 2 | Consumer Staples | 34.29% |
| 3 | Industrials | 6.42% |
Similar funds
PTC
NI
CBA
KC
EWS
IHG
SCM
PPC
Broadwood Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Broadwood Capital held 7 positions worth $867M, up 20% from $720M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 0%. Broadwood Capital opened no new positions and made no exits, leaving the 7-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 47% a quarter earlier, followed by Consumer Staples and Industrials.
- Broadwood Capital added most to Insight Molecular Diagnostics in Q4 2019, an estimated $2.12M increase.
- Broadwood Capital's ten largest holdings make up 100% of its $867M portfolio in Q4 2019.
- Broadwood Capital opened 0 new positions and closed 0 in Q4 2019.
- Broadwood Capital's portfolio value rose 20% quarter-over-quarter to $867M.
Based on Broadwood Capital's 13F filing for Q4 2019, filed 14 Feb 2020.